Advertisement

Chapter 16: Development of Robust Lyophilization Process for Therapeutic Proteins: A Case Study

  • Ehab M. Moussa
  • Tong Zhu
  • Feroz JameelEmail author
Chapter
  • 88 Downloads
Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 35)

Abstract

Biotherapeutics is a general term that describes several different therapeutic modalities that are produced by biological means. Such modalities include proteins, peptides, RNA, gene therapy, cell therapy, vaccines, etc. Among these modalities, therapeutic proteins constitute the largest class of approved products as well as new biological entities (NBEs) in development. Therapeutic proteins encompass a large number of different modalities including monoclonal antibodies, antibody-based molecules, protein conjugates, fusion proteins and enzymes.

Keywords

Lyophilization Formulation Robustness Stability 

References

  1. 1.
    Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203:1.CrossRefGoogle Scholar
  2. 2.
    Patel SM, Nail SL, Pikal MJ, Geidobler R, Winter G, Hawe A, et al. Lyophilized drug product cake appearance: what is acceptable? J Pharm Sci. 2017;106:1706.CrossRefGoogle Scholar
  3. 3.
    Johnson RE, Kirchhoff CF, Gaud HT. Mannitol–sucrose mixtures—versatile formulations for protein lyophilization. J Pharm Sci. 2002;91:914.CrossRefGoogle Scholar
  4. 4.
    Chang LL, Pikal MJ. Mechanisms of protein stabilization in the solid state. J Pharm Sci. 2009;98:2886.CrossRefGoogle Scholar
  5. 5.
    Zhu T, Moussa EM, Witting M, Zhou D, Sinha K, Hirth M, et al. Predictive models of lyophilization process for development, scale-up/tech transfer and manufacturing. Eur J Pharm Biopharm. 2018;128:363.CrossRefGoogle Scholar
  6. 6.
    Searles JA, Carpenter JF, Randolph TW. Annealing to optimize the primary drying rate, reduce freezing-induced drying rate heterogeneity, and determine T′gpharmaceutical lyophilization. J Pharm Sci. 2001;90:872.CrossRefGoogle Scholar
  7. 7.
    Cicerone MT, Pikal MJ, Qian KK. Stabilization of proteins in solid form. Adv Drug Deliv Rev. 2015;93:14.CrossRefGoogle Scholar
  8. 8.
    Wang B, Tchessalov S, Cicerone MT, Warne NW, Pikal MJ. Impact of sucrose level on storage stability of proteins in freeze-dried solids: II. Correlation of aggregation rate with protein structure and molecular mobility. J Pharm Sci. 2009;98(9):3145–66.CrossRefGoogle Scholar
  9. 9.
    Cicerone MT, Douglas JF. β-Relaxation governs protein stability in sugar-glass matrices. Soft Matter. 2012;8:2983.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2020

Authors and Affiliations

  1. 1.Formulation Development, New Biological Entities, AbbVie (United States)North ChicagoUSA

Personalised recommendations